Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SAB-142

Other · developed by SAb Biotherapeutics

Phase 3 Most advanced trial
SABS Developer
2 Registered trials

What is SAB-142?

SAB-142 is an intravenously administered investigational agent studied in type 1 diabetes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Endocrine
Developer
SAb Biotherapeutics, Inc. (SABS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07670650 Phase 3 Type 1 Diabetes (T1D) Not yet recruiting SABS
NCT07187531 Phase 2 Type 1 Diabetes Recruiting SABS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Type 1 DiabetesType 1 Diabetes (T1D)

More from SAb Biotherapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SABS page.

Follow SABS, the company behind SAB-142

See SABS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SABS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.